No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Neumora Therapeutics, Inc. Common Stock (NMRA) stock was $0.49 as of Oct 6, 2026, 11:50 AM EDT, down 5.81% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.1% · 3-year avg -64.8%/yr
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions.
Biotechnology · Watertown, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.19
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.23
vs Estimate
$-0.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NMRA | $91.68M | $0.49 | -5.81% | -71.12% | N/A | N/A | N/A |
| 2ECOR | $91.24M | $10.12 | -0.10% | +101.52% | -8.10% | N/A | vs NMRA |
| 3EQ | $90.73M | $1.44 | -1.03% | -3.34% | -26.99% | N/A | vs NMRA |
| 4RLYB | $90.54M | $17.06 | +0.95% | +271.55% | -35.80% | N/A | vs NMRA |
| 5BMEA | $93.27M | $1.29 | -0.77% | -39.39% | -36.56% | N/A | vs NMRA |
| 6PMVP | $89.60M | $1.68 | -5.62% | +23.49% | -43.17% | N/A | vs NMRA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$6.14
+1141.5% upside
Low
$3.00
Current
$0.49
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.21 | $-0.20 | $-0.18 | 6 |
| Quarter ending Dec 2026 | $-0.20 | $-0.18 | $-0.14 | 6 |
| Quarter ending Mar 2027 | $-0.15 | $-0.15 | $-0.15 | 2 |
| Quarter ending Jun 2027 | $-0.16 | $-0.16 | $-0.16 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.99 | $-0.91 | $-0.71 | 7 |
| FY 2027 | $-0.89 | $-0.64 | $-0.30 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $625000.00 | $625000.00 | $625000.00 | 9 |
| FY 2027 | $2.90M | $2.90M | $2.90M | 5 |
